← Human Trials & Peer-Reviewed Studies
A randomized trial of nortriptyline combined with transdermal nicotine for smoking cessation
Plain-language guide to PMID 15534159 (2004): double-blind randomized controlled trial study of Therapeutic nicotine (patch, non-peptide).
Key Facts
- PMID
- 15534159
- Journal
- Archives of internal medicine
- Year
- 2004
- Study type
- Randomized Controlled Trial
- Authors
- Prochazka AV et al. (5 authors)
- DOI
- 10.1001/archinte.164.20.2229
- Registered trial
- NCT00018148
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Therapeutic nicotine (patch, non-peptide), published as a randomized controlled trial.
Smoking cessation rates with current therapy are suboptimal.
The researchers hypothesized that addition of nortriptyline hydrochloride to transdermal nicotine would enhance cessation rates.
Who Took Part
The age groups tagged for this paper are teenagers, adults, middle-aged adults and older adults, both men and women.
The researchers conducted a randomized, double-blind, placebo-controlled trial at a Department of Veterans Affairs medical center.
Subjects were aged 18 to 65 years, smoked 10 or more cigarettes per day, and did not have current major depression.
How the Study Was Run
In design terms this was a randomized, double-blind and placebo-controlled study.
Because people in this Therapeutic nicotine (patch, non-peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Blinding on both sides kept the participants and researchers unaware of who received Therapeutic nicotine (patch, non-peptide).
A placebo (an inactive look-alike) gave the Therapeutic nicotine (patch, non-peptide) group a baseline to be compared against.
The behavioral intervention consisted of 12 brief, individual visits.
What Was Measured
PubMed files the paper under topics including Administration, Cutaneous, Nicotine, Nortriptyline, Probability, Risk Assessment, Smoking and Smoking Cessation.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Therapeutic nicotine (patch, non-peptide).
The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2004 (Archives of internal medicine), a journal based in United States.
More context: the Therapeutic nicotine (patch, non-peptide) compound page.
Our Notes on the Compound
Therapeutic nicotine (patch, non-peptide): Pure nicotine as a signaling tool, separated from smoking and vaping.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.